# Thomas U. Marron

Source: https://onco.cc/people/thomas-marron/  
OnCo record `thomas-marron` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Showed that neoadjuvant immunotherapy can produce major pathologic responses in liver cancer.

## Summary

Thomas U. Marron is Director of the Early Phase Trials Unit at The Mount Sinai Hospital and Tisch Cancer Institute. He is known for showing that neoadjuvant immunotherapy can produce major pathological responses in liver cancer, leading perioperative cemiplimab studies in hepatocellular carcinoma. His selected paper reports a single-arm phase 2 trial of neoadjuvant cemiplimab for resectable hepatocellular carcinoma. He runs Mount Sinai's early-phase unit and leads window-of-opportunity trials.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Early Phase Trials Unit
- Specialisms: Neoadjuvant immunotherapy; Liver cancer; Phase 1 trials

## Sources

- Mount Sinai profile: https://profiles.mountsinai.org/thomas-u-marron
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Marron%20TU%5BAuthor%5D

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Cemiplimab](https://onco.cc/drugs/cemiplimab/)
- institutions: [The Mount Sinai Hospital / Tisch Cancer Institute](https://onco.cc/institutions/mount-sinai/)
- terms: [Neoadjuvant / adjuvant / perioperative](https://onco.cc/terms/neoadjuvant-adjuvant/)

---
JSON: https://onco.cc/api/v1/entities/thomas-marron.json